Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Cost-Effectiveness Analysis Based on a Multicenter Clinical Trial

K. Ijaz; P. D. McElroy; T. R. Navin

doi:10.1086/421783

Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Cost-Effectiveness Analysis Based on a Multicenter Clinical Trial

Clinical Infectious Diseases ◽

10.1086/421783 ◽

2004 ◽

Vol 39 (2) ◽

pp. 289-289

Author(s):

K. Ijaz ◽

P. D. McElroy ◽

T. R. Navin

Keyword(s):

Clinical Trial ◽

Cost Effectiveness ◽

Latent Tuberculosis Infection ◽

Latent Tuberculosis ◽

Cost Effectiveness Analysis ◽

Tuberculosis Infection ◽

Multicenter Clinical Trial ◽

Effectiveness Analysis ◽

Short Course

Download Full-text

Short‐Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Cost‐Effectiveness Analysis Based on a Multicenter Clinical Trial

Clinical Infectious Diseases ◽

10.1086/380966 ◽

2004 ◽

Vol 38 (3) ◽

pp. 363-369 ◽

Cited By ~ 18

Author(s):

Robert M. Jasmer ◽

David C. Snyder ◽

Jussi J. Saukkonen ◽

Philip C. Hopewell ◽

John Bernardo ◽

...

Keyword(s):

Clinical Trial ◽

Cost Effectiveness ◽

Latent Tuberculosis Infection ◽

Latent Tuberculosis ◽

Cost Effectiveness Analysis ◽

Tuberculosis Infection ◽

Multicenter Clinical Trial ◽

Effectiveness Analysis ◽

Short Course

Download Full-text

Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2018.07.014 ◽

2019 ◽

Vol 73 (1) ◽

pp. 39-50 ◽

Cited By ~ 5

Author(s):

Jonathon R. Campbell ◽

James C. Johnston ◽

Lisa A. Ronald ◽

Mohsen Sadatsafavi ◽

Robert F. Balshaw ◽

...

Keyword(s):

Cost Effectiveness ◽

Latent Tuberculosis Infection ◽

Latent Tuberculosis ◽

Cost Effectiveness Analysis ◽

Tuberculosis Infection ◽

Effectiveness Analysis

Download Full-text

PIN26 COST EFFECTIVENESS ANALYSIS TO TREAT LATENT TUBERCULOSIS INFECTION: CAMPARING ISONIAZID, RIFAMPIN AND RIFAMPIN/PYRAZINAMIDE

Value in Health ◽

10.1016/s1098-3015(10)72933-8 ◽

2010 ◽

Vol 13 (3) ◽

pp. A191

Author(s):

D Sangani

Keyword(s):

Cost Effectiveness ◽

Latent Tuberculosis Infection ◽

Latent Tuberculosis ◽

Cost Effectiveness Analysis ◽

Tuberculosis Infection ◽

Effectiveness Analysis

Download Full-text

FRI0482 Cost effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before anti-tnf therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.1609 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A538.1-A538

Author(s):

C. François ◽

B. Granger ◽

G. Carcelain ◽

P. Ravaud ◽

X. Mariette ◽

...

Keyword(s):

Cost Effectiveness ◽

Diagnostic Tests ◽

Latent Tuberculosis Infection ◽

Latent Tuberculosis ◽

Cost Effectiveness Analysis ◽

Tuberculosis Infection ◽

Effectiveness Analysis

Download Full-text

Rifampin vs. Isoniazid for Treatment of Latent Tuberculosis: A Cost-Effectiveness Analysis Based on a Multicenter Clinical Trial.

10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a1018 ◽

2009 ◽

Cited By ~ 1

Author(s):

K Esfahani ◽

A Aspler ◽

D Menzies ◽

K Schwartzman

Keyword(s):

Clinical Trial ◽

Cost Effectiveness ◽

Latent Tuberculosis ◽

Cost Effectiveness Analysis ◽

Multicenter Clinical Trial ◽

Effectiveness Analysis

Download Full-text

Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial

Annals of Internal Medicine ◽

10.7326/0003-4819-137-8-200210150-00007 ◽

2002 ◽

Vol 137 (8) ◽

pp. 640 ◽

Cited By ~ 128

Author(s):

Robert M. Jasmer ◽

Jussi J. Saukkonen ◽

Henry M. Blumberg ◽

Charles L. Daley ◽

John Bernardo ◽

...

Keyword(s):

Clinical Trial ◽

Latent Tuberculosis Infection ◽

Latent Tuberculosis ◽

Tuberculosis Infection ◽

Multicenter Clinical Trial ◽

Short Course

Download Full-text

Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis

BMC Medicine ◽

10.1186/s12916-017-0865-x ◽

2017 ◽

Vol 15 (1) ◽

Cited By ~ 15

Author(s):

Guillaume A. Mullie ◽

Kevin Schwartzman ◽

Alice Zwerling ◽

Dieynaba S. N’Diaye

Keyword(s):

Cost Effectiveness ◽

Healthcare Workers ◽

Latent Tuberculosis Infection ◽

Latent Tuberculosis ◽

Cost Effectiveness Analysis ◽

Tuberculosis Infection ◽

Effectiveness Analysis ◽

Annual Screening

Download Full-text

Cost-effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before TNF-blockers therapy

La Presse Médicale ◽

10.1016/j.lpm.2017.09.029 ◽

2018 ◽

Vol 47 (2) ◽

pp. e9-e13 ◽

Cited By ~ 1

Author(s):

Romain Freund ◽

Benjamin Granger ◽

Cécile Francois ◽

Guislaine Carcelain ◽

Philippe Ravaud ◽

...

Keyword(s):

Cost Effectiveness ◽

Diagnostic Tests ◽

Latent Tuberculosis Infection ◽

Latent Tuberculosis ◽

Cost Effectiveness Analysis ◽

Tuberculosis Infection ◽

Tnf Blockers ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness of M. tuberculosis specific Interferon-gamma release assay testing for the treatment of latent tuberculosis infection in Switzerland

Pneumologie ◽

10.1055/s-2007-973117 ◽

2007 ◽

Vol 61 (S 1) ◽

Author(s):

R Diel ◽

P Wrighton-Smith ◽

J Zellweger

Keyword(s):

Cost Effectiveness ◽

Interferon Gamma ◽

Latent Tuberculosis Infection ◽

Latent Tuberculosis ◽

Tuberculosis Infection ◽

Interferon Gamma Release Assay ◽

Release Assay

Download Full-text

Faculty Opinions recommendation of Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.6673957.6829054 ◽

2010 ◽

Author(s):

Pranab Haldar ◽

Rakesh Panchal

Keyword(s):

Cost Effectiveness ◽

Latent Tuberculosis Infection ◽

Latent Tuberculosis ◽

Cost Effective ◽

Tuberculosis Infection ◽

Nice Guidelines ◽

High Burden

Download Full-text